Acta med. nagasaki. 11 : 97 123
Gaschromatographic Analysis of Urinary 17-Ketosteroids in Young Japanese Adults
Hitoshi TSUJI*
Department of Hygiene, Nagasaki University
School of Medicine, Nagasaki, Japan
Received for Publication June 1,1966
Urinary excretion of individual 17-ketosteroids in 18 normal young adults has been investigated using HC1O4/EtOAc hydrolysis and GLC over a period
of 13 months for a total of 702 determinations. Average outputs of total
17-KS were 4.77 ±1.91 mg/day in nine males and 3.60±1.44 mg/day in nine
females. The difference in total 17-KS output between the sexes was mainly
due to Androsterone excretion. Fractional patterns showed significant
personal differences and a relative constancy within each subject. The average patterns are presented, and their significance discussed. Significant
variations were shown (p<0.001) both in 11-Desoxy-17-KS and 11-Oxy-17-KS
with two peaks in summer and winter. The ranges of the seasonal variation in total 17-KS excretion were approximately ±40% in the male and ±30%
in the female. Rates of the variation were greater in 11-Oxy-17-KS and
Etiocholanolone than in 11-Desoxy-17-KS and Androsterone, respectively.
Thus, 11-Desoxy/11-Oxy and Andro/Etio ratios varied generally to the opposite direction of changes in 17-KS excretion, i. e. , high in spring and
autumn, and low in summer and winter. Average 11-Desoxy/11-Oxy -values
were 8.35 and 7.18, and average Andro/Etio values were 1.54 and 1.03, in
the male and female, respectively. Among the meteorological factors, air
temperature was the most responsible factor for variation in 17-KS output.
Beyond the optimal range of 10-20°C, a significant increase in 17-KS
excretion occured. Influences of other factors upon 17-KS excretion are
The following abbreviations and common names are used:
Androsterone (Andro) 3a-Hydroxy-5a-androstan-17-one
Etiocholanolone (Etio) 3a-Hydroxy-58-androstan-17-one
Dehydroepiandrosterone (DHEA) 3b-Hydroxyandrost-5-en-17-one 11-Hydroxyandrosterone (11-OH-A) 3a, 110-Dihydroxy-5a-androstan-17-one 11-Hydroxyetiocholanolone (11-OH-E)3a, 11-Dihydroxy-5-androstan-17-one 11-Ketoandrosterone (11-0 A)3a-Hydroxy-5a-androstane-11, 17-dione 11-Ketoetiocholanolone(11-0-E) 3a-Hydroxy-5P-androstane-11, 17-dione
*辻 均
97
98 H. TSUJ1 Vol. 11
described. Greater stability in the female than in the male, with changes in the external environment, was suggested.
This investigation was dene as the first step of a trial to obtain more extensive and reliable information about normal urinary 17‑ketosteroids excretion in the Japanese.
Many methods devised to determine individual 17‑ketosteroids (17‑KS) are based on the electrophotometric assay after the Zimmermann reaction, with one or more chromatographic systems. Difficulties encountered in these systems are; questionable accuracy, cost and time consumed. A relatively practical, yet reasonably accurate methods has been described by DePaoli and co‑workers in 1963 (1). This method is a combination of perchloric acid/ethyl acetate hydrolysis, conversion of 17‑KS to its trime‑
thylsilyl ether, and gas‑1iquid chromatography using a polar stationary phase. A slight modification of this method was employed in this inves‑
tigation .
No little things remain unexplained about urinary 17‑KS excretion, and the relationships between the adrenal or a.ndrogenic activities and the physical, nutritiona.1 or other environmental elements. It is expected that more accurate and unbiased knowledge will become evident by extending the analysis to the norn]al and pathological in different age groups.
MATERIALS & METHODS
The subjects were nine males and nine females, all medical and nursing students in their
early twenties, Iiving in Nagasaki.
The average values of height, weight and body surface area of the subjects through the investig‑
ation are listed in Tab. 1.
Twenty‑four hour urine specimens were pooled mostly on weekdays, three times monthly for thirteen months, from April'65 to April' 66. Samples during menstruation were not used in female subjects.
Urine specimens were collected from 0800 on one day to 0800 on the following day with 3 to 5 ml of toluene. One tenth of the 24 hour urine sample was filtered, adjusted to pH 4.0 or lower with 50% sulfuric acid, extracted with ethyl acetate (EtOAC) twice, dehy‑
drated with anhydrous sodium sulfate (Na2S04) and evaporated
Height , area of
Table weight
sub jects 1.
and surf ace
subJect* height
(cm) weight
( kg) body surface (m2)**
Fl F2 F3 F4 F5 F6 F8 F7 F9
mean
Ml M2 M3 M4 M5 M6 M7 M8 M9
mean
F:
l 56 . l 49 . l 52 . l 45 . l 50 . l 58 . l 58 . l 48 .
153.
l 52 .
169.
171 . l 65.
170.
155 . 167 . 168.
181 . 165 . 168 .
, M
.423 8 9 o 5 8 5 o 9 5 7 4 3 7 5 2 2 7 9 8 4
54 . 13 56 , 1 2 47 . 30 43, Il 48 , 39 57 . 22 64 , 83 46 , 60 43 , 45 51 . 24 53 . Ol 64 . OO 52 . OO 56 , Ol 45 , 24 52 . 21 59 . 45 62 , 1 7 58 . 49 55 , 84
l l.
l.
l.
l l l.
l.
l.
l l.
l.
l.
l l.
l.
l.
l.
1 l
. 492 4?l 381 291 . 387 . 538 61 8
354 341 . 430
555 696
52 l . 59g
373 532 628 742
. 5g8 . 583
. male
** Estimated from the following formula (48) S = W0･423 x H0･651 x 102.65
* f emale
1966 GLC OF URINARY 17‑KS IN YOUNG ADULTS 99
to dryness with a rotary suction‑evaporator.
Solvolysis was done with some modifications of the methods of DePaoli et al. (1) and lbayashi et al. (2'). Detailsf are as follows : The urine extract was dissolved in 100 ml of EtOAc. After the addition of 0.1 ml of 60% perchloric acid (HCI04), the solution was incubated at 37'C for 3 hours, washed with 10 ml of 10 KOH twice, dehydrated with anhydrous Na2S04 and evaporated to dryness with the suction‑
evaporator. The residue was dissolved in 10 ml of I KOH/ethanol to cleave acetates, incubated at 37'C for 2 hours, extracted with 30 ml of a mixture of petroleum‑ether/benzene I : I (v/v) twice, dehydrated with anhydrous Na2S04 and evaporated to dryness to the pure 17‑KS.
Conversion to the trimethylsilyl (TMSil) ethers was done according to the method described by Chamberlain et al. (3). The residue was dissolved in 0.5 ml of pyridine with 0.2 ml of hexamethyl‑disilazane, and after 10 drops of trimethylchlorosilane were added, incubated at 37'C for 60 minutes. After evaporating to dryness, the TMSil ether of 17‑KS was dissolved in 500 mcl of hexane, and 5 mcl of the solution (1/1000 amount of 17‑KS in 24 hour urine) was used for gaschromatogra‑
phy. Three 11‑Desoxy‑17‑KS; Androsterone (Andro), Etiocholanolone (Etio) and Dehydroepiandrosterone (DHEA), and four 11‑0xy‑17‑KS ; 11‑Hydroxyandrosterone (11‑0H‑A), 11‑Hydroxyetiocholanolone (11‑0H‑
E), 11‑Ketoandrosterone (11‑0‑A) and 11‑Ketoetiocholanolone (11‑0‑E), were analyzed. Figure I . is one of the chromatograms.
Rg I Chromatogram of urinary 17‑KS TMSit ethers
o
1:,
<
o 5 o
UJ < < I LLJ O
I O x
10 20
RETENTION TIME Imin)
3'o
A11 reagents and solvents used were analytic grade. Ethyl
was distilled again and dehydrated. Continuous attention was acetate paid to
keep the reagents, especially pyridine, dry for TMSil ether conversion.
A Shimadzu, model GC‑1B, instrument with hydrogen flame ioniza‑
tion detector was used in this investigation. The support was Chro‑
mosorb W, 60‑80 mesh, coated with 2 cyanoethyl silicone polymer (XE‑60), Ioaded into a 2.25 meter stain]ess steel column with an internal diameter of 4 mm. The operating conditions were as follows: Colurnn bath temperature of 210'C, with flash heater maintained at 260QC and detector cell at 250'C, the inlet pressure of‑ nitrogen of 3.0 kglcm2 flow rate 25 ml/min.
The peak area was calculated by the following formula : area = (half‑height Width) x (Height). Small or unsatisfactorily separated areas were estimated by direct measurement and calculation. The calibration curve of 17‑KS TMSil ethers was checked before the inve‑
stigation, being almost linear as to the amounts of the original 17‑KS up to about 10 mcg. Furthermore, a standard solution of cholestane was used for the quantitative analysis of 17‑KS TMSil ethers to eliminate possible variations in the detector sensitivity. The standard solution was prepared of cholestane/hexane (1 mcg/3 mcl), 6 mcl of which was applied to every series of gaschro‑
Table 2. matographic analysis . The same
Retention times relative, to amount, 2 mcg, of both cholestane
Androsterone (210'O (O and 17‑KS TMSil ethers (KS)
ere applied alternately to gas‑
Andro 1.00 hromatography to obtain a chole‑
Etio I . 1 DHEA 1.3s stane/ketosteroid ratio (C/KS).
ll‑OH‑Andro 1.5 The individual urinary 17‑KS ll‑OH‑Etio 1.89 were calculated by the following l I ‑o‑Andro 2 . 1 7 equation :
11‑0‑Etio 2.49 17‑KS= (C/KS)･Ps/Pc (mg/day) Cholestane 1.19 Where, Ps=peak area of a steroid
= rom a chromatogram, and Pc = Table 3. Recovery of free 17 ketostercuds
Andro
Etio
DHEA
ll‑OH‑A l 1‑0H‑E l I ‑O‑A l I ‑O ‑ E
urine mg
O . 57 + o . I O*
O . 34 + o . 09 O . 07 O . 02 O . 06 +̲ O . Ol
O O
0.01 0.02
added mg
3.0 2,6 2.6
O,q̲
2.4 3.0 2.2
( )
(5) (5) (5) (5) (5) (5) (4)
ex pected mg
3 . 57 2 . 94 2. 67 O . 96 2 . 40 3 . OO 2 . 21
f ou n d mg
3 . 32 h̲ O . 06*
2 . 93 0 . 1 2 2 . 56 O . 06 l . 19 O . 06 l . 69 0 .08 2 . 38 O . 08 l .69 0 .03
recovery
93
l OO
96
l 24
70 79 76
(n) : Number of determinations
* Standard deviation
1966 GLC OF URINARY I ‑Ks IN YOUNG ADULTS 101
peak area of I mcg of cholestane, estirnated from applying the standard solution. The C/KS ratios of each 17‑KS were renewed any time when possible change of analytic conditions, i. e. , exchange of column or battery, or washing of detector cell, occured. Values of C/KS were 1.00 to 1.03 in the 11‑Desoxy‑17‑KS group, and 1.13 to 1.38 in the 11‑
Oxy‑17‑KS group throughout the investigation.
Of the standard steroids and cholestane used, 11‑0H‑Andro and 11‑0‑Andro were obtained from lkapharm, Ltd., Israel. Other steroids and cholestane were the products of Steraloids, Inc., New York. Retention times of these steroids are shown in Tab. 2.
Recovery of the individual 17‑KS was examined with a normal urine specimen, and known amounts of pure 17‑KS added in a minimal amount of ethanol solvent to the same pool of urine. Table 3 presents the study of recovery. The proportion of urinary total 17‑KS recovery, estimated from the average pattern of the fractionation, was approxi‑
mately 97 per cent.
RESULTS & DISCUSSION
Tables 4 & 5 summarize the basic data of the individual 17‑KS determinations. The figures shown in the tables are in mg/day, rounded to one decimal. The thirteen months' average excretion of total and individual 17‑KS, and the fractional patterns in percentage are listed in Tab. 6. Urinary outputs of DHEA and 11‑0xy‑17‑KS are distributed in a probable Poisson series. Th^erefore, the standard deviations of these steroids are not shown in the table.
Total 17‑KS:
The average excretion of 4.77 1.91 mg/day in the male and 3.60 1.44 mg/day in the female was a little lower than expected. A
significant difference between the male and female was shown (p<0.001) . Several studies have been maGle of the excretion of 17‑KS in Japanese adults (4 & 5). The lowest of those values obtained by using the method of Zirnmermann are average excretions of 12 mg/day in the male and 7 mg/day in the female. Ernest et al. (6) , however, indi‑
cated that the urinary excretion of <<true" 17‑KS, obtained by chroma‑
tographic separation after enzyme hydrolysis, corresponded to about 40
‑50% of the values obtained by the routine method of Norymberski
(7). He gave an average of 7.4 mg/day as the <<true" value from
55 students of both sexes. This value does not differ much from
those values presented for European subjects (8, 9 & 10) . It is evident
that as will be mentioned later in this paper, there exist regional
differences in 17‑KS excretion mainly due to climate. It would seem
reasonable, therefore, to assume that the values in the present study
represent the average output of true 17‑KS in young adults living in
s̲outhwestern Japan,
102
Table
H．TSUJI
4． Basic data，tota117−Ketosteroid（mg／day）
170Z．11
subject Apr 3．8 F1 3．4 2．6 3．8 F2 4．3 5，4 5．1 F3 5．9 5．6 2．3 F4 3．0 2．5 5．6 F5 3．3 4．9 4．O F6 3．5 3．7 4．l F7 4．1 2．8 3．7 F8 1．7 4．3 3．5 F9 4，3 4．9 4。8
Ml 7．0
6．1 4．5
M2 4．5
4．0 6．1 M3 5．3 5．0 5．7
M4 2．9
4．3 6．3
M5 4．2
4．5 8．8
M6 8．0
4．2 6．4 MI1 7．8 5．7 6．2 M8 5．1 4．6 4．7 M9 3．2 4．7
May Jun JuI Aug Sept Oct Nov Dec Jan Feb Mar Apr mean
2．5 2。1 3．3 4．6 3．5 3．3 4，6 3．2 3．l l．7 1．5 2．1 5．7 6．2 2，2 3．3 2．2 2。3 4．7 5．7 4．7 3．2 3．2 5．1 3．0 2．8 3．7
7．2 5．2 4．3 3．4 3．8 3．9 4．6 4．4 4．8 4．7 4．8 4．4 7。1 5．0 2。2 6．6 8．3 6．7 4．5 6，4 5．4 6．3 5。5 3．8 5．4 9．4 4．5
3．0 2．8 2．9 3．5 3．6 1．8 4．3 4．O l．7 2．8 2．8 2．0 6．8 4．6 3．8 2．9 3．0 1．9 4．8 2．6 3．9 5．9 3．5 26
5。1 4．2 2．5
5．1 5。0 4．0 2．8 2．4 2．7 5．7 4．3 4．4 5．8 4．8 4．4 4．3 2．9 4．8 5。4 3．6 4．3 6．3 4．2 3．2 3．8 4．3 4．6 3．3 2．0 6．8
3．1 1．9 2．5 3、3 3．4 3．9 2．9 2．5 5．2 1．2 3．4 2．5 5．3 6，9 5．0 2．5 3，1 3．3 5．3 5．0 6．6 4，7 5．0 4．2 3．9 2．4 2．1
6．9 7．4 6．3 6，0 7．1 5．2 5．3 6．6 7．0 5．8 7．6 8．0 4．6 7．7 5．3 5．2 6．4 7，5 7．6 8．3 5．8 6．1 5．8 5．7 8．3 7．3 3，8
2．2 1．6 2．0 3．6 4．1 4．4 4．5 6．9 4．0 3．0 2．8 3．0 8．7 8．4 5．3 6．4 4．4 4．3 5．5 5．3 4．7 4．8 5．8 6．6 4．9 4．4 3．1
8．2 4．5 4．5 7。4 1．9 5．O
lO．4
2．5 5，6 8．5 6．3 6．3 5．8 8．6 5．O
l2，2
5．5 7．7 9．8 9．3 7。3 6．7 4．6 8．7
10。2
7．6 2．6 3．8 3．3 3．1 1．3 3．3 3．3 2．6 2．7 1．3 2．1 2．6 6．0 4．7 4．9 8．6 3．0 3．0 3．6 5．6 4．9 4．9 4．4 4．0 3．5 3．3 2．3
6．1 6．6 4．8 2．5 4．7 4．8 7．6 5。4 5．5 5．2 5．6 5．8 4．5 4．4 5．0 7．7 7．4 6．0 6．2 4．7 6。1 5．3 4。0 3．9 3．4 3．2 4．O
2．0 3．2 2．8 2．9 3．2 2．6 3．9 3．2 2．9 2．5 1．0 1．5 4．3 5．0 6．3 2．9 3．0 2．6 8．3 3．7 4．4 4．2 3．9 3．4 3．3 3．9 3．6
5．7 4．3 4．3 6．1 5．2 2．6 6．0 4。3 5．4 5．4 2．9 3．2 4．3 3．7 3．4 6．4 4．2 4．9 3．7 2．8 3．7 3．7 3．2 2．6 5．3 2．0 3．9
3．0 2．2 2．8 2．8 4．2 3．0 2．8 3。2 3．3 1．8 1．8 1，8 3．4 7．5 3．8 2．9 2．3 2．3 3．5 3．2 3．7 3．0 3．1 3．8 2．4 1．9 3．9
3．5 3．5 5．1 1．8 2．1 4．2 5．2 2．5 3．6 4．6 4．6 3．9 3．1 2．0 2．7 4。7 1．7 5．9 2．3 2．7 3．4 4．5 1．3 1．5 4．3 2．6 4．O
2．6 2．9 2．9 3．0 2．8 1．6 1．7 2．5 5．1 3．4 3．0 3．4 2．9 3．9 3．7 3．4 4．2 3．5 4．7 4．2 2．6 3．6 3．9 3．7 4．2 5．6 6，1 2．0 2．3 2．4 2．4 1．7 3．l l．9 2．6 2，4 4．4 6．0 8．2 4．5 6．8 4．4 4．7 12。1 7．5 2．6 4．5 4．3 2．9 3．3 3．8 2．4 3．9 3．6 3．9 3．9 4．8 4．3 5．4 4．2 5．5 6．7 4．0 3．6 7．2 4．8 2．8 5．8 4．3 2．6 6．2 6．5 2．9 3．4 4．9 3。7 3．7 4．1 3．2 3．9 5．6
工．7 2．4 2．5 1．7 2．6 3．2 2．2 2．0 4．O l．2 1．5 0。7 6．1 3．5 3．l l．7 3．2 1．4 2．6 2，5 2．2 1．5 3．8 1．8 2、4 4．5 2．1
2．6 2．4 3．0 3．3 2．3 2．4 4．1 3．4 1．4 3．6 1．6 1．4 7．3 5。0 2，4 3．1 1．7 2．3 3．1 5．2 2．2 2。9 3．8 3．6 2．3 2．3 3．8
2．70
3．33
3．77
2．15
5．43
3．11
4．31
4．11
10．1
3．48
4．0 4．6 5．1 4．3 2．7 1．7 3．9 5．8 3．0 5．6 5．0 4．4 4．1 2．7 2．8 5．3 1．5 6．2 4．1 3．7 4．5 3．3 4．3 1．8 4．4 8．5 5．5
5。1 3．0 3．6 2．6 4．3 6．7 4．3 3．5 5．8 5，7 5．5 6．2 8．6 3．3 4．0 2．9 5．7 7．0 6．1 5．0 5．Q 4．0 4．9 4．6 4．4 3．4 6．8
9．4 4。2 3。3
10．0
1．8 4，8 5．4 5．2 3．7 7．7 4．9 4．5 8．0 5．7 2．5 9．1 7．1 4．7 5．2 4．4 3．2 8．0 3．4 5．7 7．4 4．7 7．4
2．2 2．0 3．7 2．3 1．6 0．7 3．3 7．0 3．7 2，3 1．9 2．4 4．1 3．1 3．5 3．8 2．7 4．3 2．0 3．7 4．6 4．6 2．2 3．3 4．1 4．1 4．8
2．1
1．0 4，82 4．4
1．8
2．9 3．83 2，6
4。3
4．2 4．97 3．3
1．8
3．2 4．88 3．6
1．0
2．7 4．33 1．6
5．9
5．0 5．83 4．1
3．4
2．0 5．02 3．4
0．8
1．2 4。28 3．0
2．1
3．6 4．99
3．8
1966 GLC OF URINARY l7・KS IN YOUNG ADULTS 103
Table 5−1． Androsterone（mg／day）
subject Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr
F1 1．7 1．1 1．3 0．8
1．2 ］．3 1．8 2．l
F2 1．8 1．4
1．9 1，5 2．1 2．l F 3 2．4 1．3 2．4 1．1 1．5 1．3
F4 1．5 0．9
1．2 0，8 2．1 1．8 F 5 1．1 2．2 1．7 1．3
F6 F7
1．8 1．4 1．6 0，9 1．7 1。1 2．1 2．2 1．9 2．7 1。2 2．0 2，3 1．6 F 8 0．9 1．5 2．2 2．5 1．5 1．6
F9 2．0 1．4
2．3 1．7
M1 2．7 3．0 2．5
2．9 M2 2．3 2．0 3．O M3 2．5 2．3 2．5 M4 1．5 2．2 2．4 M5 2．2 1．7 2．5 M6 2．4 1．3 3．O M7 3．5 2．6 3．6 M8 3．3 2．6 2．2 M9 1．7 1．9
3。0 2．4 2．1 1．9 2．3 2．4 2．3 2，1 2．4 2．5 2．5 2．6 2．9 2．2 1．1 2．1 2．4 1．9 2．3 3．3 2．8 3．8 3．3 2．2 2．6 3．4 2．6
1．3 1．O l．3 1．6 1．8 1．1 1．8 1．7 0．8 2．1 1．5 1．2 2．3 1．4 1．3 1．4 1．3 0。7 2．2 1．3 2．0 2．8 1．8 1．3 2．4 2．O l．1
2．7 2，7 2．4 1．9 1．6 1．7 3。0 2．5 2，4 3．7 3．0 2．6 1．9 1．5 2．1 1．9 1．6 1．6 3．6 2．6 1．7 2．5 2．8 2．8 1．6 1．1 3．3
1．0 0．8 1．0 0．6 0．8 0．7 1．4 1．4 1．4 1．6 1．5 1．6 1．O l．6 0．9 1．7 1．7 1．4 0．7 1．4 1．5 1．0 1．2 1．5 1．5 1．5 1．6 1．6 1．2 1．8 1．2 1．5 1．1 1．O l．1 1．1 1．9 2．0 1．9 2．0 2．1 2．0 2．2 2．3 2．2 2．9 1．7 3．0 1．4 1．9 1．O l．7 1．0 1。3
3．2 3．6 3．0 3．2 3．8 3．1 2．5 3．3 3．1 3．0 4．1 4．3 2．3 3．0 2．4
］．9 3．3 2．0 3．6 3．4 3．8 3．4 3．5 3，6 2．9 3．9 3。4
4．0 2。2 2．5 3．6 1．1 2．7 4．3 1．3 2．9 4．2 3．7 3．8 2．4 3．2 2．0 3．7 3．4 2。8 4．4 4．2 3．0 2．6 2．6 2．5 4．3 3．5 1．9
0．8 0．8 1．1 1．O
l．5 1．3 0．9 1．2 1．2 1．0 1．0 0．7 1．5 1．3 1．3 1．7 0。9 1．6 2．0 1．6 1．5 1．5 1．4 1．5 1．3 1．7 1．6 2．O l．2 1．4 1．6 1．7 1．2 1．4 1．5 1．8 0．7 1．4 1．1 1．1 1．0 0。6 1．O l．3 1．4 0．9 −1．0 1．1 1．8 1．7 1．7 1．3 1．4 1．8 2．7 1．6 1．5 2．4 1．3 1．5 1．4 1．O l．4 0．9 1．2 1．2 1．O l．O l．2 1．1 0．9 1．0 1．3 2．2 1．7 1．6 2．1 1。6 1．6 1．7 1．8 1．8 』2．0 2．2 2．4 2．0 1．7 1．8 2．2 1．9 1．7 1．4 2．0 1．9 2．2 1．3 1．7 1．5 1．2 1．4 1．5 1．9 1．O l．7 1．1 2．0 2．4 1．5
2．9 3．5 2、4 1．3 2．9 2．5 3．9 2．6 2．4 3．0 3．2 3．2 1．9 2．0 2．0 2．7 2．8 2．1 3．0 2．6 2。9 3．3 2．4 2．3 1．6 1．4 2．0
3．1 2．6 2．3 4．3 3．3 1．8 3．0 2，3 2．8 3．1 1．9 2．0 2．O l．6 1．6 2．3 1．7 1．9 1．9 1．5 1．9 2．2 2．0 1．7 2．6 1．0 2．0
1．7 1．8 2．6 1．3 1。4 2．8 2．6 1．3 1．8 2．9 2．6 2．4 1．5 1．O l．4 2．2 0．7 2．4 1．2 1．7 1．7 2。8 0．9 1．1 2．3 1．4 2。2
2．2 2．3 2．6 2。9 1．7 0．8 1．9 3．l l．6 3．4 3．3 2．6 1．9 1．3 1．4 2．0 0．6 2．3 2．0 2．0 2．5 2．0 2．8 1．1 2．5 4．4 2．8
1．0 0．9 0．6 0．9 0．8 0．5 0．7 0．8
0．6 1．5 1．l l．O
1．1 1．4 0．7 1．4 1．7 1．6 1．2 0．8 1．8 1．0 1．5 1．0 1．3 0．7 0．6 1．5 1．2 1．1 0．6 1．5 2．O l．9 1．6 0．8 1．2 1．1 0．6 1。2 1．3 1．4 0．9 0．7 1．2 1．2 0．5 0．7 1。7 2．2 1．5 1．7 1．9 2．O l．1 1、2 2．8 1．6 0．9 0．7 1．5 1．3 0、6 1．0 1．3 1．6 1．3 0．7 1．4 1．4 0．4 0．9 1．5 1．7 1．1 1。2 1．8 1．6 1．1 1．8 2．1 1．3 0．8 0．8 2．9 1．l O．8 1．4 2．4 1．7 1．8 1．7 2．6 2，6 0．9 1．7 2．0 1。8 1．0 1．1 1．4 1．5 1．9 0．9 1．5 1．9 0．8 1。5
2．6 1．4 1．8 1．8 2．3 4．1 1．9 1．5 2．9 3．2 3．0 3．4 3．2 1，2 1．4 1．2 1．9 2．4 2。9 2．2 2．4 2．5 2．8 2．9 2．3 1．5 3．4
4．3 1．6 1．4 6．2 1．2 2．6 2．4 2．2 1．3 4．0 2．6 2．5 2．8 2．0 0．9 3．0 2．0 1．2 1．9 1．8 1．4 4．3 2．0 3．1 3．4 2．2 3．3
1．2 0．9 2．1 1．3 1．O O．4 1．3 2．7 1．6 1．3 1．1 1．5 1．7 1．7 1．6 1．1 0．9 1．4 0．8 1。9 2．2 2．5 1．3 2．1 1．9 1．7 2．5
1．1 0．6 2．0 1．1 1．7 1．5 1．7 1．8 1．6 1．l l．8 2．0 0．5 1．2 0．6 1．8 1．7 1．4 1。3 1．O
l・。7
0．4
0．6
1．8
1．1
1．7
1．7
104 H．TSUJI 701．11
Table 5−2． Etiocholanolone（mg／day）
sublect Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr
F1 1．7 1．6 1．2
1．8 F2 1．8 2．2 2。4 F3 2．2 2．4 O．7 F4 1．1 0．9 2．4 F5 1．O l．8 1．5 F6 1．0 1．5
F7 1．8 1．6 1．2
1．2 F8 0．5 1．4 1．3 F9 1．3 1．2
1．3 1．6 1．！ l．2 1．6 1．1 2．0 1，4 1．4 1．4 1．5 0 2．0 2．1 1．4 1．6 0．9 0．7 O．3 0．6 0．5 1．O O．8 0．5 2。1 2，4 2．2 1．5 0．7 0．8 1．2 0．7 0．9 1．2 1．O O．2 1．5 1．9 2．0 0．9 1．7 1．0 1．2 2．2 1．1 1．1 2．0 0．8 O。8 1．5 0．5 1．3 1．2 0．6
1．6 0．5 1．2 1．0 1．3 1．2 1。5
！，2 2．2 0．5 1．2 0．8 2．0 3．0 1。8 1．1 1．2 1．4 2．1 2．3 2．7 1．7 1．9 1．5 1．3 0．9 0．6
1，0 0．7 0．9 1．3 1。1 1．9 1．8 3．7 1．9 1．3 1．6 1．3 4．1 2．0 2．1 3．2 2．7 2．2 2．4 2．5 1．9 1．7 2．0 2．2 2．3 1．8 1．3
1．2 1．0 1．4 1．3 1．8 1．6 1．2 1．6 1．6 1．5 1．4 0。9 1．1 1．0 1．2 1．3 0．4 1．3 1．7 1．1 1．2 1．0 1．l l．4 1．4 1．5 0。9 2．2 1．1 1．3 1。1 1．5 1．l l．2 1．3 1．8 0．1 0。9 0．6 0．7 0．9 0．4 0．7 0．9
1．0 0 0．6 0．7
2．O l．8 1．3 1．6 1．8 2．0 3．0 1．4 1．4 2．8 1．4 1．7
1。6 1．5 1．3 1．O l、5 1．6 1．7 1．7 2．9 0．9 0 1．1 2．6 2．8 4．1 1．4 1．3 1．1 1．0 1．7 1．3 1．3 1L．0 1，4 1。4 1．2 1．1 0．9 1．O l．7 1．5 2．4 1．3 1．6 1．5 2．6 1．7 1．2 1．7 2。1 2．3 2．2 1．4 1．9 2．6 1．7 1．7 1．1 1．4 2。5 1．7 1．4 1。3 0．8 1．8 1．4 1．3 1．l O．8 2．2 1．3 1．2 0．8 0．9 0 1。3 1．4 0．6 1．1 1．3
09 1．l l．1 1．O l，7
1．5 0．8 1．3 0．9 1．3 1．1 2．5 0．9 1．5 1．3 0．6 1．l l．3 1．1 0．8 1．8 1．0 0．9 1．4 1．2 1．7 1．8 0．9 1．4 3，0 1．6 0．3 1．1 0．5 1．9 1．2 0．5 0．7 1．0 0．2 0．5 4．2 2．4 2．6 1．・6 1．3 1．6 3．O O．4 0．7 2．0 0．7 1．5 1．2 1．4 0．6 1．0 0．7 0．9
・2．0 1．O l．2 1．7 0．9 2．1 2．O O．9 1．1
］．．8 0．5 0．9 1．7 1．4 1．3 2．6 Q．3 ：L．2 1，9 1．0 0．6 1．5 1．5 0．8 2．1 0．4 1．4
1．7 M1 2．6 2．3 1．3 M2 1．5 1．5 2．5 M3 2．1 2。O 2．l M4 0．5 1．5 3．2 M5 1．8 2．1 3．7 M6 4．2 1．9 2．7 M7 2．5 2．3 1．7 M8 1．5 1．4 1．9 M9 1．0 1．9
2．7 1．9 1．6
！．2 1．1 1，1 1．7 1．6 1．3 1．3 1．2 0．9 3．1 2．0 0。9 2．7 3．4 2．5 1．3 2．1 0 1。7 1．4 0。8 1．6 3．0 0．4
1．7 1．7 1．3 0．7 0．5 0．6 1．9 1．4 1．6
！．4 1．2 1．1 1．6 1．1 1．8 2．1 1．1 1．5 1．7 0．5 1．1 O．8 1．0 1．2 0．9 0．6 2．3
2．4 2．7 2．4 1．5 1．7 1．3 1．7 2．3 2．1 1．5 1．8 2．0 1．7 2．8 2．O 2．4 3．9 2，5 2．3 2．8 2．4 1．6 1．5 1．3 1．6 2．5 1．8
2．8 1．6 1．3 1．9 0．6 1．4 3．2 0．8 2．0 1．9 1、7 1．5 1．3 3．8 2．4 4．3 1．4 3．1 2．3 3．1 2．6 1．2 1．3 3．3 2．4 2．5 1，1
2．2 2．4 1．9 0．6 1．4 1．2 2．9 1。8 1。6 1．4
！．6 1．8 2．0 2．0 2．2 2．9 2．4 2．1 2．3 1．6 1．9 1．4 1．1 1．1 1．5 1．1 1．3
2．O l．4 1．5 1．4 1．6 0．7 2．3 1．6 1．9 1，7 0．8 0。9 1．9 1．3 1．2 2．6 1．5 1．9 1．1 0．9 1．4 1．l O．9 0．8 2．0 0．7 1．2
1．1 1，1 1．9 0．3 0．6 1．2 1。9 0．6 1．1 1．3 1，2 1．O 1．4 0．5
1．、1
2．O O．3 2．1 0．8 0．5 1．2 1．1 0．4 0．3 1．3 0．7 1．2
1．4 1．7 1．7 1．2 0。6 0．4 1．2 1．8 0．9 1．4 1．1 1．1 1．8 1．1 1．1 1．7 0．3 2．2 1．1 1．1 1．2 0．9 1．2 0．5 1，3 2．6 1．5
1．7 1．0 1。2 0．6 1．2 1．6 1．0 1．1 2．1 1．4 1。3 1．6 4．6 G．8 1．7 1。O l．9 3．3 1．6 1．3 1．6 O．9 1．l l．2 1．3 1．1 2。2
2．7 1．9 1．4 2．3 0．2 1．3 1．7 2．2 1．4 2．0 1．6 1．3 3．2 2．7 0．9 3．3 2．8 1．6 O．9 1．3 0．9 1．7 0．9 1．3 2。3 1．5 2．4
0．6 0．6 1．1 0．4 0．3 0．1 O．8 1．9 1．0 0．5 0．3 0．5 1．5 1．Q l．3 0．9 0．4 1．3 0．4 0．8 1．4 1．0 0．4 0．5 1．l l．0 0、2
0．8
0．4
1．6
O．5
0．7
0．6
1．3
1．6
1．3
0．4
0．7
0．9
0．4
1．0
0．7
1．7
1．7
1．3
0．9
0。5
1．2
0．2
0．2
0．8
0．7
1．2
1．2
1966
Table
GLC OF URINARY17・KS IN YOUNG ADULTS 5−3． Dehydroepiandrosterone（mg／day）
105
sublect Apr May O O Fl O．1 0 0 0 0．1 0．2
F2 0．3 0．4
0．3 0．2 0．2 0．2 F3 0．5 0．2
0。4 0．7
0．1 0 F4 0．1 0 0．1 0．4 1．O l．O
F 5 0．5 1．3
0．9 0
0．2 0．2
F6 0．1 0．1 0．1 0
0 0．3
F7．0・1 0・3 0．1 0．3 0 0．2
F 8 0．2 0．3
0．2 0．2 0．5 0．4
F9 0．4 0
0．5 0．4 Jun
O O．1 0。2 0．2 0．1 0．1 0．1 0．3 0．1 0 0 0．1 1．3 1．l l．0 0．2 0 0．1 0。1 0．1 0．3 0．4 0．3 0 0．6 0．5 0．3
Jul Aug Sept Oct Nov
O O O O O O O O O O O O O O O
O．3 0 0．1 0．3 0．1 0。2 0 0 0。1 0．1 0．4 0．3 0．3 0 0．2 0 0 0．1 0．5 0．2 0 0．3 0．1 0．1 0．l O．1 0．1 0．1 0．1 0．2
0 0 0 0 0 0 0 0 0 G O O O O O
l．1 2．2 1．2 0．5 0．3 1．3 1．1 1．l l．0 1．2 1．2 0．8 1．5 0．7 0．7
0 0．3 0 0 0 0 0 0 0 0 0 0 0 0 0
0．4 0．3 0，1 0．l O．2 0．2 0 0．1 0．1 0．2 0．3 0．l O．2 0．1 0 0．3 0．4 0．3 0．2 0．1 0．3 0．5 0．2 0．3 0 0．3 0．8 0．工 0 0．2 0，5 0．1 0．l O．1 0．2 0．l O．2 0．2 0．1 0．1 0．1 0 0 0．l O。2
Dec
O．1 0 0 0．1 0．1 0．2 0．3 0．3 0．4 0。1 0 0 0．9 1．0 1．0 0．1 0．1 0．1 0．2 0．4 0．7 0．2 0．4 0．4 0．4 0．6 0．4
Jan Feb Mar Apr
O．1 0。1 0．1 0．1 0．1 0 0 0．1
0．1 0．2 0 0．l O．3 0．3 0。2 0．3 0．2 0．3 0。1 8。4 0。2 0．5 0．3 0．2 0。7 0．1 0．2 0．3 0．5 0．3 0．3 0．3 0．4 0．3 0．3 0．1 0．1 0 0 0．2
0．1 0．1 0 0．1 0．1 0 0 0．1
1．2 0．7 1．6 2．O l．5 0．4 0．7 1．7 3．2 2．O l．6 0．9 0．3 0 0．1 0．2
0．1 0 0．1 0．1
0．1 0 0．2 0．1 0．3 0．3 0．2 0．2 0．7 0．2 0．2 0．4 0．7 0．1 0．2 0．2 1．4 1．3 0．1 0．4 1．l O．6 0．2 0．4 0．8 0．7 0．4 0．4 1．0 0．6 0．2 0．3 0．7 0．6 0．6 0．2 0．3 0．7 0．8 0．5
O
M1 0。3 0．3
0
M2 0．1 0．2 0．4 M3 0．5 0．4 0．5 M4 0，1 0．2 0．2 M5 0．1 0．2 1．2 M6 0．5 0．5 0．5 M7 1．5 0．6 0．2 M8 0．l O．2 0．3 M9 0．4 0．5
0．2 0。2 0 0．1 0．1 0 0．3 0．3 0．4 0．4 0．4 0．3 0．3 0．3 0．1 0．9 1．4 1。4 0．6 0．7 0 0．1 0．3 0．2 0．9 1．9 0．1
0 0 0 0 0 0 0．4 0．1 0．3 0．3 0．1 0．2 0．4 0．1 0．3 0．7 0．7 0．5 0．5 0 0．3 0．1 0．1 0。2 0．4 0．2 0．6
0．1 0 0 0．3 0．3 0 0．5 0．5 0．7 0．5 0．4 0．6 0．2 0．5 0 0．6 1．8 1．0 0．9 0．6 0．8 0．1 0．3 0．3 0．5 1．O l．0
0 0 0．1 0 0 0 1．2 0．3 0．4 1．4 0．4 0．2 0 0．3 0 2．1 0．1 0，9 1．6 0．6 1．0 0。4 0．2 1．8 1．3 0．7 0．2
O．1 0 0 0 0 0 0。4 0．4 0．6 0．2 0．3 0．2 0．1 0．1 0．1 1．0 1．l l．1 0．4 0．3 0．9 0．1 0．1 0．1 0．1 0．2 0．2
0．1 0 0 0 0 0 0．5 0．1 0．3 0．l O O．1 0 0．6 0．5 0．7 0。8 0．9 0，6 0．3 0．3 0．1 0．1 0 0．3 0．2 0．5
0．1 0．l O O O O O．3 0．5 0．3 0．1 0．3 0．2 0．2 0．4 0 0．3 0．6 0．9 0．3 0．1 0．2 0．2 0 0 0．3 0．3 0．2
O．1 0．1 0。2 0 0．1 0．1 0．7 0．6 0．3 0。3 0．3 0．4 0．1 0．2 0，2 1．2 0．6 1．1 0．8 0．5 0．6 0．1 0．1 0．1 0．4 0．9 0．9
0．2 0．1 0．1 0．1 0．2 0 1．2 0．6 0．3 0．5 0．4 0．3 0．3 1．2 0．3 0．4 1．6 0．6 1．3 0．9 0．7 0．4 0．4 0．3 0．3 0．3 0．6
0．6 0．3 0．1 0．2 0．2 0．2 0．8 0．4 0．5 0．7 0，3 0．3 0．8 0．5 Q．5 1．5 1．6 1．4 2．1 1．O O．9 1．O O．3 0．7 1，1 0．7 1．1
O．2 0．2 0．2 0．2 0．2 0．2 0．9 1．4 1．0 0．2 0．4 0。3 0．6 0．3 0．3 1．3 1．2 1．2 0．8 0．8 0．7 0．7 0．3 0．5 0．8 1．1 0．1
O．1
0
0．2
0．1
0．2
0．2
0．9
0．6
0．2
0．2
0．3
0．2
0．1
0．2
0．1
1．8
1．1
1．1
0．9
0．4
0．3
0．2
0．2
0．2
0．2
0．3
0．6
106 H．TSUJI γoJ．11
Table 5−4． 11−Hydroxyandrosterone（mg／day）
subject Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr
F l
F2 F3 F4 F5 F6 F7 F8 F9
0．3 0．1 0．2 0．1 0．1 0．1 0。1 0．1 0．2 0．2 0．8 0．1 0．3 0．2 0．5 0。3 0．3 0．3 0 0．1 0．2 0．1 0．3 0．1 O．l O．4 0．2 0．2 0．3 0．1 0．5 0．5 0．6 0、3 0．3 0．2 0．2 0．3 0．2 0．3 0．3 0．4 0．1 0．2 0．1 0．3 Q．4 0，3 O．2 0．2 0．4 0．2 0，6 0．4
O．1 0．2 0．2 0．2 0．1 0．2 0．3 0．1 0．2 0．3 0．1 0．5 0．3 0．2 0．3 0．2 0．1 0．4 0．1 0 0．3 0．3 0．1 0．2 0．3 0．3 0．4 0．4 0．1 0．3 0．5 0．1 0．3 0．4 0．2 0．4 0。5 0．4 0．2 0．3 0．2 0．6 0．4 0．3 0。3 0．3 0．3 0．4 0．6 0．4 0．4 0．3 0．4 0．2
0．2 0．1 0．2 0．5 0．7 0．6 0．5 0．3 0．3 0．2 0．2 0。2 O．5 0．4 0．4 0．3 0．5 0．5 0．4 0．4 0．4 0．4 0．4 0．6 0．3 0。5 0．4
0．3 0．1 0．2 0．1 0．2 0．1 0．4 0．3 0 0．2 0．3 0．1 0。3 0．2 0．2 0．3 0．3 0．2 0．2 0．2 0．2 0 0．2 0．2 O．4 0．2 0．2 0．2 0．4 0．3 0．7 0．4 0，3 0．4 0．5 0。4 O．4 0．3 0．4 0．2 0．4 0．2 0．5 0．3 0．3 0，3 0．4 0．2 0．4 0．5 0．3 0．4 0．3 0．4
0．2 0．1 0．2 0．2 0．4 0．3 0．l O．2 0．3 0．1 0．l O．2 0．1 0．3 0．3 0．3 0．2 0．4
0．1 0．1 0．2 0．1 0。1 0．1 0．2 0．1 0．2 0．2 0．1 0．2 0．4 0．3 0．2 0．3 0．3 0．4 0．2 0．4 0．1 0．3 0．5 0，2 0．2 0．2 0．6 0．2 0．3 0．3 0．2 0．3 0．2 0，1 0．3 0．1 0．3 Q．3 0．1 0．2 0．2 0．3 0．4 0．3 0
∩．1 0．1 0．2 0．1 0．2 0。2 0．2 0．4 0．1 0．1 0．1 0．2 0．2 0 0。1 O．4 0．3 0．6 0．3 0．6 0．3 0．4 0．4 0．2 0，3 0．3 1．0 0．6 0．1 0．1 0．3 0．6 0．6 0．2 0．3 0．3 0．4 0．7 0．3 0。3 0．3 0．4 0．8 0．1 0．3 0．2 0．3 0．3 0．5 0．2 0。2 0。2 0．4 0．4 0。2 0．2 0．3 0．7 0．3 0．2 0．1 0．2 0．4 0．4 0．1 0．1 0．2 0．3 0．3 0．3 0．3 Q．l O．5 0．5 Q．1 0．2 0。2 0．2 0．5 0．2 0．2 0．3 0．2 0．5 0。4 02 0．3 0．4 0．6 0．1
0．3 0．4 0．1 0．2 0．3 0．2 0．3 0．3 0．3
M1 M2 M3 M4 M5 M6 M7 M8 M9
0．1 0．4 0．4 0．3 0．4 0．3 0．2 0．2 0．3 0．6 0．2 0．3 0．2 0．l O．2 0．6 0．2 0．2 0．2 0．2 0．2 0．7 Q．2 0．4 0．3 0．1 0．3
0．5 0．3 0。3 0．2 0．3 0．4 0．2 0．3 0．3 0．3 0．4 0．5 0．2 0．2 0。1 O．3 0．5 0，4 0．2 0．2 0．4 0．5 0．5 0．2 0．3 0．5 0．6
0．4 0．3 0。2 0．2 0．2 0．3 0．3 0．1 0．1 0．3 0．4 0．4 0．2 0．1 0．2 0．3 0．l O．2 0．3 0 0．1 0．4 0．3 0．4 0．3 0。1 0．3
0．4 0．5 0．4 0．7 0．5 0．4 0．3 0．3 0．4 0．5 0，6 0．6 0．1 0．6 0．3 0．1 0．2 0．3 0．3 0．4 0。2 0．5 0．5 0．4 0．3 0．3 0．5
0．7 0．4 0．4 1．1 0．2 0．6 0．9 0．1 0．3 O。4 0．4 0．5 O。4 0．5 0．2 O．9 0．6 0．4 0．4 0．3 0．3 0．4 0．2 0．4 O．9 0．7 0．6
0．4 C．4 0．3 0．5 0．4 0．7 0．3 0．4 0．3 0．6 0．5 0．6 0．2 0．1 0．3 0．5 0．6 0．4 0，3 0．2 0．3 0．5 0．4 0．4 0．2 0．3 0．5
0．3 0．1 0．2 0．4 0．3 0．1 0．2 0．2 0．3 0．5 0．2 0．2 0。2 0．1 0．1 0．4 0．1 0．1 0．1 0．1 0．1 0．3 0．2 0．1 0．4 0．1 0．2
0．3 0．4 0．2 0．2 0．1 0．2 0．3 0．1 0．4 0．3 0．4 0．3 0 0．1 0．2 0．1 0．1 0．3 0 0．1 0．3 0．4 0 0．1 0．4 0．2 0．4
0．1 0．2 0．3 0．2 0．2 0．1 0．1 0．2 0．2 0．4 0．3 0．3 0．1 0．1 0．1 0．2 0 0．3 0．2 0．1 0．2 0．3 0．2 0．1 0．2 0．5 0．3
0．3 0．3 0．3 O．1 0．4 0．8 0．1 0，2 0．4 0。4 0．7 0．8 0．2 0．1 0．3 O．2 0．2 0．3 0．2 0．4 0．2 0．2 0．6 0．2 0．4 0．4 0．6
1．0 0．2 0．2 1．2 0．1 0．5 0．4 0．3 0．3 0．9 0．4 0．4 0．6 0．2 0．1 0．8 0．3 0．3 O．3 0．2 0 1，0 0．2 0．4 0．6 0．3 0．5
0，1 0．1 0．3 O．3 0．1 0 0．2 0．5 0．1 0．3 0．1 0。1 0．2 0．1 0．1 0．2 0．1 0．2 0 0．1 0．1 0．4 0．1 0．2 0．2 0．2 0．3
0．1
0
0．3
0．1
0．2
0．2
0．3
0，2
0．2
0．1
0．3
0．4
0
0．2
0．1
0．2
0．3
0．2
0．2
0．1
0．1
0
0．1
0．2
0．1
0．4
0．3
1966
Table subject Apr May
GLC OF URINARY l7・KS IN YOUNG ADULTS
5−5． 11−Hydroxyetiocholanolone（mg／day）
Jun Jul Aug Sept Oct Nov Dec Jan Feb
107
Mar Apr
F l
F2 F3 F4 F5 F6 F7 F8 F9
0．1 0．1 0．1 0 0 0．1 0 0．1 0．1 0 0．1 0 0 0 0 0 0 0 0 0 0 0 0 0．1 0 0 0
0 0．2 0．2 0 0．1 0 0 0 0 0 0 0 0．1 0 0。1 0．3 0．2 0．1 0 0 0 0 0 0 0 Q O．1
0 0．1 0．1 0．1 0 0 0 0 0。1 0 0 0 0．2 0．1 0 0 0 0 0．1 0．1 0．1 0 0 0 0 0 0
0 0．2 0．2 0．1 0．1 0。1 0 0．2 0．1 0 0。2 0．4 0 0．2 0．2 0 0．3 0 0 0．2 0．5 0 0．2 0．6 0 0．7 0．1 0 0 0．1 0 0．4 0 0 0．3 0
0．2 0．2 0．2 0．1 0．4 0．1 0．3 0．4 0．1 0 0．1 0．3 0 0．3 0．1 0 0。3 0．1 0 0．3 0．1 0 0．3 0．1 0 0．5 0．1 0 0．1 0 0 0．3 0 0 0．3 0 0 0．1 0．2 0 0．1 0 0 0．1 0
0．1 0．1 0．1 0 0 0 0．1 0 0 0 0 0 0．4 0 0 0 0．1 0 0．1 0．1 0 0 0 0 0 0 0
0 0．2 0 0 0
0。1 0 0．1 0．1 0 0．1 0．1 0 0．2 0．2
0 0 0 0．3 0 0 0 0 0．2 0 0 0 0 0 0 0 0 0 0．1 0．1 0 0 0 0．1 0．1 0 0 0 0 0．3 0 0 0 0 0 0 0 0 0．1 0 0 0 0 0 0
0 0 0．1 0 0．3 0 0．1 0。1 0 0
0 0 0．1 0。7 0 0．l O O．1 0．2 0．2 0 0．1 0 0 0．2 0 0 0 0．2 0．3 0．1 0 0．1 0．1 0．1 0 0 0．1 0。1 0．1 0 0 0．1 0．3 0．1
0 0 0 0 0．1 0 0 0 0．1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0．1
0 0．1 0．1 0．1 0．1 0．1 0 0．1 0 0．1 0．1 0 0 0．2 0 0
0．1 0 0 0．1 0 0 0 0 0．1 0．3 0．1 0．2 0．1 0 0 0．1 0 0 0 0．1 0 0。1 0 0．3 0．1 0 0 0
0．1 0．1 0．1 0．1
0 0 0 0．1 0 0．1
M l
M2 M3 M4 M5 M6 M7 M8 M9
0．3 0．1 0 0 0 0 0 0 0 0 0．1 0 0．2 0．1 0 0．1 0．2 0．2 0 0．1 0 0 0 0 0 0．2 0
0．1 0 0 0 0 0 0 0 0 0 0 0 0 0 0．2 0．1 0 0 0 0 0 0 0 0 0．1 0 0．1
O．4 0．3 0．3 0．3 0．5 0．3 0．3 0．2 0．5 0．3 0．5 0．4 0．3 0，6 0．5 0．2 0．5 0．4 0，4 0．4 0．7 0．2 0，3 0．2 0．4 0．6 0．6
0．4 0．1 0。1 0，6 0 0．1
0．6 0 0 0．5 0 0．1 0．3 0。3 0．2 0．8 0
0．2 0．6 0，3 0．2 0，6 0．1 0．2 0．8 0．1 0
0．2 0．1 0．1 0 0 0．3 0 0 0．5 0 0 0 0．l O．l O．1 0．2 0．2 0．1 0．1 0
0．1 0 0 0 0 0．1 0
0．1 0 0．1 0 0 0 0 0．1 0 0 0 0 0．1 0 0 0．1 0 0 0 0 0 0 0 0 0 0 0
0．1 0。1 0．1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0．1 0 0 0 0 0 0 0 0 0
0．l O．1 0．1 0 0 0 0 0 0 0 0 0 0．1 0 0 0．r O O．1 0 0 0 0 0 0 0 0．1 0
0．l O．1 0．1 0 0．1 0．1 0 0 0 0．1 0 0 0．1 0
0．2 0 0 0．2 0
0．2 0 0 0 0 0．1 0．l O
0．4 0．1 0．1 0 0 0．1 0 0 0．1 0 0 0 0．3 0．1 0
0．2 0．1 0．1 0 0 0 0 0 0．1 0 0 0．1
0 0，1 0 0 0 0 0 0．3 0 0 0 0 0 0 0．1 0．1 0 0。1 0 0．1 0．1 0 0 0 0．1 0．1 0．1
O O O．2 0 0．1 0．1 0 0 0 0 0．1 0．1 0
0．1 0．1 0．2 0．1 0．1 0。l O
O．1 0
0。1
0
0
0
0
108
subject Apr
F l
F2 F3 F4 F5 F6 F7 F8 F9
M l
M2 M3 M4 M5 M6 M7 M8 M9
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0．l O O O O O O O O O O
O O
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Q O O O O O O O O O
Table 5−6．
H。TSUJI
11−Ketoandrosterone（mg／day）
70」。11
May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar ．Apr
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 Q O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O Q O O O O O O O O O O O O O O O O O O O O
0 0 0 0 0 0 0 0 0 0 0 0 Q O O O O O O O O O O O O．1 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 Q O O O O O O O O O O O O O Q．1 0。1 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0．1 0
0 0 0 0 0 0 0 0 0 0 0 0 Q O O O O O O O O O O O．1 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Q O O O O O O O
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 G O O O O O O O O O O O O O Q O O O O O O O O O O O O O O O O O O O O
0 0 Q O O O O O O O O O Q O O O O O O O O O O O O O O
O O O．1 0 0 0 0 0 0 0 0 0 0 0 0、
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 Q O O O O O．1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0。1 0 0 0 0 0 0 0 0 0 0．1 0 0 0 0 0 0 0 Q O．1 0 0 0 0
0 0 Q O O O O O O O O O Q O O O O O O O O O O O O O O
0 0 0 0 0 0 0 0 0 0 0 0 Q O O O O O O O O O O O O O O
0 0 0 0 0 0 0 0 0 0 0 0 Q O O O O O O O O O O O O O O
O O O O O O．2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Q O O O．1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0
0
0 0
0
0 0
0
0 0
0
Q 0
O
O O
Q
O O
O
O O
O
O O
O
1966
Table
GLC OF URINARY l7、KS IN YOUNG ADULTS
5−7． 11−Ketoetiocholanolone（mg／day）
109
subject
Fl F2 F3 F4 F5 F6 F7
F8．
F g
Ml M2 M3
雑4
M5 M6 M7
Mピ
M9
Apr May O O O．1 0
0 0。2 0 0。l O．2 0．1
Q．1 0
0．1 0．1
0．2 0 0 0 0 0 0 0 0 0
0 0．2 0．5 0．2 0．2 0．1
0 0 0．1 0 0．1 0 0 0．3
0．3 0．3 0 0．2
0．1 0
0 0
0 0．1 d o
O．2 0．7
0．3 0
0．3 0。5 0．5 0．3 0．4 0．3
0 0 0．1 0 0 0
0 0．l
O O．1
0， 0・4 0 0．2 0．6 0．2 0．1 0．3 0．2 0．4
0 0．2 0．2 0
0．5 0．5 0．5 0．4 0．2 0．3
0 0．l O．l O
O 2，2 0 0．2 0 0
0．0．4
0 − O O O．4
0−0．8 Jun
O O．2 0．2 0 0．1 0．5 0 0．1 0 0 0 0．1 0．3 0．1 0．3 0．1 0．2 0．7 0．1 0．1 0．4 0．1 0 0，2 0 0 0．l
O．2 0．3 0．l Q O．1 0．l O．1 0．2 0 0．1 0．1 0．1 0．2 0．1 0．2 0．3 0。1 0．5 0．2 1．1 0 0 0．1 0 0 Q O．2
Jul Aug Sept Oct Nov Dec Jan Feb IMar Apr
0．l O．1 0．1 0，3 0 0 0 0 0．1 0 0 0 0．2 0．2 0．1 0 0．1 0．1 0．2 0 0．4 0．1 0 0 0．1 0
0・．1
0．4 0．3 0．2 0 0．3 0．1 0 0 0．2 0 0．2 0．1 0 0．2 0．1 0 0．4 0．2 0 0 0．4 0 0 0 0 0 0
0 0。1 0．1 0 0．5 0 0．1 0。3 0．2 0 0 0 0．2 0．2 0．！
0．8 0 0．3 0．3 0．3 0．2 0 0 0 0．1 0．2 0．l
O．3 0．2 0．1 0．2 0 0．2 0．2 0 0 0．1 0．1 0．2 1．4 0．5 0，2 0．4 0 0．3 0．5 0．8 0．2 1．5 0．2 0．β 0．5 0 0
0．2 0．l O．2 0．1 0．2 0．1
0 0 0 0 0 0 0．1 0 0 0．1 0 0
0．3 0 0 0 0 0．4
0．2 0．1
0．2 0
0．l O．1 0．1 0．1 0．1 0．l
O．1 0
0．2 0．2 0．3 0．1 0．2 0．1
0 0
∩ ∩
0 0 0 0
0 0．1
0 0
−O．3 0．1 0．2 0．2 0．1 0．2
0．1 0 0 0
0．1 0 0．1 0
・O．2 0 0．1 0．1
0 0 0 0 0 0
0．2 0．1 0．l O，l
O．1 0
0．4 0．3 0．3 0．1 0．2 0．1
0．1 0 0 0 0 0 0 0
0 （）
0 0 0 0 0．1 0 0 0
0．1 0 0．1 0 0 0 0 0．2 0 0 0 0 0 0。2 0．1 0．1 0 0，1 0。1 0 0．1 0 0 0 0 0 0
0．2 0 0．2 0 0 0 0．1 0 0 0 0．1 0 0 0 0 0．l O O．1 0 0．3 0 0 0 0 0 0 0
0．l O O O O O O O O O O O O．1 0．1 0．1 0．1−
O．1．
O O．l O．2 0．2 0 0 0 0 0 0
0．1 0．2 0．2 0 0．1 0．l O O．1 0 0．1 0 0 0。1 0 0 0．ユ O Q．2 0 0 0 0 0 0 0 0 0
0．！
O，1 0．1 Q O O O．1 0。1 0 0 0 0 0．2 0．2 0．3 0．2 0．1 0．1 0．2 0．3 0．3 0 0．1 0．1 0．1 0．1 Q
0．1 0．1 0．1 0．1 0．1 0．1 0．3 0．1 0。1
0 0 0 0 0 0
0 0 Q
O，1 −O．1 0．1
0．1 0．1 0
0．2 0．1 0．2
0 0 0
0 ・O O
O O O
O．2 0．2 0．1
0 0．l O O．3 0 Q O。2 0。1 Q O．1 0．1 0 0．1 0 Q
O．2 0．1 0．1 0．2 0．1 0．2
0．2 0 0 0．1 0 0
0 0 Q
O．1 0 0 0．1 0 0 0 0．1 0 0．2 0 0
0．2 0。1 0．1 0 0。1 0．1 0．1 0．1 0．1 0．1 0．1 0．1 0．2 0 0．1 0．1 0．1 0．2 0．1 0 0 0 0 0 0 0 0
0．4 0．l O．1 0．l O．1 0．l O．1 0．1 Q．1 0．1 0 0 0．3 0．2 0．1 0．3 0．3 0．1 0 0．1 0 0 0 0．1 0 0 0
0．1 0．1 0 0．1 0 0 0．1 0．2 0 0 0 0 0．1 0 0．1 0．2 0．1 0．1 0 0 Q．1 0 0．1 0 0 0 1．6
0
0
0．1
0
0
0
0．1
0
0
0
0
0
0
0
0
0．2
0．1
0
0
0
0
0
0
0
0
0
0
110 H．TSUJ1 レρ」．ノ1
Table 6．
Average and percentage excretion of individua117−ketosteroids
female male
Mean土SD ％ Mean±SD ％
Andro
Etio
DHEA
l1・OH・A ll・OH・E ll・0・A ll・0−E Tota117・KS
1．45 土 0．50 1．41 ニヒ 0．66
0．30 0．28 0．07 O．003 0．09
3．60 土 1．44
40．3 39．2
8．3 7．8 1．9 0．0 2．5 100．0
2．32 土 0．88 1．51 ± 0．77
0．43 0．30 0．09 0．002 0．12
4。77 土 1．91
48，6 31。7
9．0 6．3 1．9 0．0 2．5 100．0
It is generally accepted that17−KS excretion shows considerable variation related to race，body build，or nutritional state． Though it is impossible to discuss ethnic specialities from the present data，it is believed that17−KS excretion in higぬer in Europeans than in other races
（11，12，13＆14）． It is probably true that the differences between
them are due to differences in Table7． body size，climate，nutritional or Correlations in17−ketosteroid socio・econmic states（15）．
excretion（Pく0．001） The body build of the subjects c蕊fficien乏of （Table1）was nearly that of the
correlation between
correlation
Total KS＆11−Desoxy・KS
＆ 11−Oxy・KS ＆Andro ＆Etio折 ＆DHEA ＆11−OH−A ＆11・OH・E ＆11−0・E l1・Desoxy−KS＆11・Oxy−KS Andro！Etio＆Total KS Alldro＆Etio
EtiQ＆DHEA DHEA＆Andro
11・Desoxy−KS＆Andro
＆Etio ＆DHEA ll・Oxy・KS＆ll・OH・A ＆11・OH−E ＆11 0・E
female O。976 0．655 0．768 0．904 0．675 0．629 0．434 0．285 0．536
−0．333 0．601 0．477 0。335 0。796 0．895 0．691 0．780 0．701 0．643
male O．962 0．715 0．837 0．865 Q．476 0．673 0．626 0．343 0．586
−0。272 0．596 0．382 0．122＊
0，844 0．882 0．504 0．683 0．711 Q．739
＊P＜O．05
average Japanese， although the male subjects studied were
slightly more slender and taller．
Relationships were examined bet−
ween average 17−KS output and body weight or body surface area．
Correlations between them were all very low（P＞0．70in male，＞
0．90in female）． This may be due to the small number of sub−
jects studied．However，although there is some correlation between steroid excretion and weight or surface area， the coefficient o：f correlation will remain low．The coefficients of correlation （r） in 101 subjects by Tanner et a1．
（16） were r−0．31 （17−KS and weight）and r−0．26（17−KS and surfacearea）。
Lugg＆Bowness have reported
1966 GLC OF URINARY 1 ‑KS IN YOUNG ADUL1'S 111
racial characteristics in six ethnic groups, expressed by a compound variate, Iog (K+1)/W, rhere K is 17‑KS excretion and W is weight (17), and also showed no difference between the sexes within an ethnic group (18). The log (K+1)/W value in this investigation was 0.0134 0.0018 on the average of all subje'cts. No significant difference was found between the sexes (0.50>p>0.40).
Malnutrition, especially a low protein diet, decreases the amount of urinary 17‑KS output (19, 20 & 21). A diet high in unsaturated fats and low in saturated fats has decreased urinary 17‑0xosteroids, especi‑
ally Etio (P<0.01) (22). Although individual dietary assa,ys were not done in this work, no actual or suspected nutritional deficiency was revealed by physical examination, nor by individual and family history.
Individual 17‑KS & Fractional Pattern :
Sex difference in individual 17‑KS excretion was found to signifi‑
cant only in Andro (P 0.001'). Thus, the principal factor in the difference between the sexes in total 17‑KS excretion was confirmed to be due to Andro output. This was suggested also by Ohashi et al.
(23) .
The coefficient of correlation (r) was calculated between several combinations of the individual 17‑KS or the fraction ratios, as listed in Tab. 7.
The coefficients between total 17‑KS and 11‑Desoxy‑17KS outputs were extremely high, and r = 0.976 in the female and r = 0.962 in the
F;g. 2. Relationship between Total 17‑KS(K] and 11‑
Desoxy‑17‑KS (D)
tn=351)
Fig. 3. Relationship between Total 17‑KS and Andro (n=351)
90
60
: 30
1:,
a E̲ a, U'
le,
>
‑ gO
60
30
female r= O 976
Llt' .II I f r .LLLI '
=1'158D‑o'068
30 60 90 120
mQ[e r=0 962
I'l' .1.
Ll It
IIF ̲
IL'
l '̲
Lf ‑ ‑‑
l' ' x=1 221D‑0'422 Il'
L8
32
,6 :h o
I' h*
r.;)E o c o
I
o S 4.8
< c
fema[e
r = O. 768
::
‑
